Creative Touch Permanent Makeup and Aesthetics

Cutibacterium acnes is named for a condition it causes only when things go wrong. On healthy sebaceous skin, it is among the most metabolically active and structurally useful organisms in the microbiome: fermenting sebum fatty acids to produce propionic acid, which activates PPARα receptors in keratinocytes and drives both barrier lipid synthesis and filaggrin expression; secreting RoxP, a radical-scavenging protein that protects keratinocytes from oxidative damage; contributing to the acid mantle environment that suppresses Staphylococcus aureus; and occupying the sebaceous niche through which it prevents more harmful organisms from establishing. It becomes a driver of inflammation not through simple overgrowth but through a phylotype community shift – when follicular conditions change, virulence-capable IA1 phylotypes dominate over the commensal IB and Type II strains, and CAMP factor-driven IL-8 inflammation follows. The distinction matters clinically across the entire lifespan: in perimenopausal skin, C. acnes relative abundance drops from 79.9% to 32.1%, removing PPARα signalling, antioxidant provision, and acid mantle support simultaneously – a triple-mechanism withdrawal that explains perimenopausal barrier deterioration more precisely than sebum decline alone. And in the clinical treatment of acne, it means the goal is phylotype rebalancing, not elimination.

Cutibacterium acnes is a gram-positive, aerotolerant anaerobe that colonises the hair follicle and sebaceous gland, where it metabolises sebum lipids as its primary nutrient source. It was formally renamed from Propionibacterium acnes in 2016 following genomic reclassification – a change that better reflects its phylogenetic position but that the clinical literature has only partially adopted, meaning older research uses the previous name interchangeably. It colonises sebaceous skin sites predominantly: the face, upper back, and chest, where sebaceous gland density and sebum output are highest. It is essentially absent in pre-pubertal skin, rapidly establishes dominance at sebarchae, and comprises approximately 50% of all bacteria at sebaceous skin sites in healthy adults. ^[6]

Its name, of course, primes a pathological reading. That is unfortunate, because the commensal biology of C. acnes is both more interesting and more clinically useful than the pathological narrative most people have absorbed.

What Commensal C. acnes Does

The most significant and underreported function of commensal C. acnes is barrier synthesis. C. acnes ferments sebum-derived fatty acids via a methylmalonyl- CoA pathway, producing short-chain fatty acids – primarily propionic acid – as metabolic end-products. Propionic acid diffuses into keratinocytes and activates PPARα (peroxisome proliferator-activated receptor alpha), a nuclear receptor that coordinates a broad lipid synthesis programme. PPARα activation upregulates GPAT3 and FASN – the enzymes that govern glycerophospholipid and fatty acid synthesis – and simultaneously drives expression of filaggrin (FLG) and loricrin (LOR), the two structural proteins central to cornified envelope formation and the generation of natural moisturising factor. ^[8] Note that FLG and LOR induction has been demonstrated in 2D keratinocyte culture models; results in 3D reconstructed epidermis systems show attenuated effects, indicating the magnitude of this response is model-dependent.

The practical translation of this is striking. A proportion of the barrier lipid synthesis happening in healthy sebaceous skin is not purely endogenous – it is co-ordinated by a microbial metabolite. This is not an incidental contribution. It is a functional overlap between host biology and resident microorganism that has been conserved across evolution precisely because C. acnes and human sebaceous skin are deeply co-adapted. Almoughrabie et al. (2023, Science Advances) confirmed this mechanism rigorously: commensal C. acnes secretions significantly induced lipid synthesis and FLG/LOR expression in keratinocyte models in a PPARα-dependent manner, with the effect abolished by PPARα inhibition and replicated by pure propionic acid. ^[1]

Acid mantle contribution. Propionic acid does double duty: alongside driving PPARα in keratinocytes, it directly acidifies the skin surface. Together with the free fatty acids generated by C. acnes lipase activity on sebum triglycerides, this produces a meaningful acidification contribution to the sebaceous-site acid mantle – maintaining the pH 4.5–5.5 environment that suppresses S. aureus and sustains ceramide-processing enzyme function. On sebaceous sites, C. acnes is the dominant acidification mechanism, in the way that eccrine lactic acid dominates on non-sebaceous sites. When C. acnes populations collapse – in perimenopause, after antibiotic treatment, or in ageing skin – this acidification function declines with them. ^[12]

RoxP: endogenous antioxidant provision. C. acnes secretes RoxP, a 15 kDa extracellular protein with radical-scavenging activity that protects keratinocytes and monocytes from oxidative stress in a dose-dependent manner. What makes RoxP particularly noteworthy is that its sequence is almost fully conserved across all C. acnes phylotypes – commensal and pathogenic alike. It is a species-level function, not a strain-specific one. On healthy skin, RoxP effectively represents an endogenous antioxidant provided by the resident microbiome, operating continuously at the skin surface without any dietary or topical supplement. Its concentration measurably declines in oxidatively stressed skin, and dysbiosis characterised by reduced C. acnes is associated with impaired oxidative defence at the cutaneous surface. Altered C. acnes community composition has been observed in association with certain skin tumours – an association that implicates loss of RoxP’s protective function as one potential contributing variable, though causal directionality is not yet established. ^[2]

S. aureus competition. Propionic acid suppresses S. aureus Agr quorum-sensing activation at concentrations achievable in sebaceous skin environments. C. acnes lipid-derived antimicrobials and occupational niche competition on sebaceous surfaces provide additional competitive pressure. The loss of C. acnes from these sites – through any mechanism – opens the sebaceous niche for S. aureus establishment.

These four functions – PPARα-driven barrier synthesis, acid mantle acidification, oxidative defence through RoxP, and S. aureus niche competition – are precisely the contributions whose simultaneous withdrawal the perimenopausal C. acnes decline documented in the HELIOS cohort represents. The 60% reduction in relative abundance is not an abstract microbiome statistic; it is a quantified withdrawal of all four.

The Phylotype Architecture: Why Strain Matters More Than Abundance

This is the point that most content on C. acnes either misses or handles superficially – so it deserves direct, unhedged treatment.

A meta-analysis of 18 studies comprising 102 healthy controls and 401 acne samples found no statistically significant difference in total C. acnes abundance between acne-affected and healthy skin. What distinguished them was the ratio of Staphylococcus to C. acnes (the S/C ratio) and the distribution of C. acnes phylotypes within the community. Acne is not a C. acnes overgrowth problem. It is a community composition problem. ^[5]

C. acnes is divided into several phylogenetically distinct groups, of which the clinically most important distinction is between:

Phylotype IA1 (pathogenic-associated): Enriched at 48.3% among infection isolates, with an odds ratio of 1.98 for invasive infection compared to commensal strains. Carries higher frequencies of CAMP factors (CAMP1–4), lipases, pore-forming toxins, and surface proteins mediating host cell adhesion and invasion. CAMP factors drive IL-8-mediated keratinocyte inflammation and trigger NLRP3 inflammasome-dependent IL-1β release. When IA1 strains dominate the follicular community, the result is the sustained comedogenic and inflammatory signalling that defines acne. ^[3]

Phylotype IB and Type II / C. acnes subsp. defendens (commensal-associated): IB strains show an odds ratio of 0.5 for invasive infection – enriched on healthy skin and associated with anti-inflammatory metabolite production. C. acnes subsp. defendens strains, formally characterised in a 2024 Frontiers in Microbiomes study, showed confirmed anti-inflammatory properties in a rosacea-like mouse model – reducing erythema, IL-6, and IL-1β compared with IA1 challenge, and significantly outperforming untreated controls. This is a strain providing active protection against inflammatory phenotypes in exactly the condition where C. acnes is rarely considered a useful ally. ^[9]

The practical implication of this architecture is that the clinical goal in acne management cannot be “eliminate C. acnes.” Eliminating the species removes PPARα signalling, RoxP antioxidant function, acid mantle acidification, and S. aureus competitive suppression simultaneously – while the remaining S. aureus and Staphylococcus populations are positioned to expand into the vacated ecological space. What the evidence supports instead is restoring phylotype balance: reducing IA1 dominance and the follicular conditions that select for it, whilst preserving and supporting the IB and Type II populations. ^[5]

When C. acnes Becomes Pathogenic

Pathogenic C. acnes activity is not an intrinsic property of the organism switched on spontaneously. It requires a changed follicular environment. The transition is driven by comedone formation and follicular hyperkeratosis – which create an enclosed, oxygen-depleted, lipid-enriched environment that selects specifically for anaerobic IA1 strains over the more metabolically flexible commensal types.

Within that environment, CAMP factor expression increases, driving IL-8 production, neutrophil recruitment, and NLRP3 inflammasome activation with IL-1β release. C. acnes lipase activity – which at healthy commensal concentrations generates the FFAs contributing to acid mantle maintenance – generates excess FFAs under high-sebum substrate conditions that trigger comedogenic hyperkeratinisation of the follicular wall. The same organism. The same biochemistry. The difference is substrate availability and follicular pH. ^[4]

This context-dependency is why the “phylotype balance” framing is more actionable than the “good bacteria vs bad bacteria” framing. Conditions that create the enclosed, anaerobic follicular microenvironment promote IA1 dominance. Conditions that maintain open follicular drainage, normal sebum flow, and healthy sebaceous-site pH maintain the ecological balance in which IB and Type II strains thrive.

C. acnes Across the Lifespan

C. acnes colonisation is entirely sebum-dependent: absent in prepubertal skin, dominant after sebarchae, and progressively declining as sebum production falls with age – particularly through and after the menopause.

The HELIOS cohort study (2025, Nature npj Biofilms and Microbiomes) quantified this decline with unusual precision: relative C. acnes abundance dropped from 79.9% in pre-menopausal women to 32.1% in post-menopausal women – a 60% reduction in the organism providing PPARα barrier synthesis, RoxP antioxidant protection, and acid mantle acidification. Notably, this occurred without a statistically significant difference in sebaceous gland activity between groups, suggesting additional menopausal factors beyond sebum reduction are driving the community shift. ^[10]

A separate 2024 metagenomic study found that the decline in C. acnes relative abundance in older skin directly correlated with reduced skin elasticity and increased wrinkle depth. ^[7] This positions C. acnes not only as an acne-relevant organism but as a structural ageing variable – one whose absence contributes to the barrier fragility and oxidative vulnerability of perimenopausal and aged skin independently of intrinsic cellular senescence. The skin that “used to look after itself” in a client’s forties was doing so, in part, because C. acnes was providing PPARα, RoxP, and acid mantle support that is now substantially withdrawn. ^[7]

Antibiotic Resistance: The Honest Picture

This is where the data warrants a frank clinical assessment rather than a diplomatic one.

Macrolide antibiotic resistance in C. acnes has risen substantially; pooled erythromycin resistance reached 29.20% (95% CI: 22.14–37.43%) in a 2025 systematic review of global data, with significant regional variation – a trajectory of escalating resistance over recent decades. Clarithromycin resistance reaches 77% in some regions. Tetracycline resistance remains relatively low. Doxycycline maintains approximately 2.44% resistance and is currently the most effective antibiotic option by resistance profile. ^[14]

The clinical consequence of this trajectory is that the macrolide-based acne antibiotic courses most commonly prescribed in the UK – typically erythromycin or azithromycin topically, clarithromycin or erythromycin orally – are now, in approximately a third of clinical presentations, treating an organism that isn’t susceptible to them. They are generating selection pressure for further resistance whilst eliminating the commensal C. acnes strains (IB, Type II) that were providing PPARα signalling, RoxP protection, and Agr suppression against S. aureus. They are solving a phylotype imbalance problem by depleting the species rather than addressing the follicular environment that created the imbalance. ^[11]

Isotretinoin’s mechanism is mechanistically distinct and resistance-free: it suppresses sebaceous gland activity through RAR/RXR receptor activation, removing the lipid substrate that C. acnes depends on, thereby reducing colonisation through habitat removal rather than direct antimicrobial action. This avoids resistance selection entirely – which is one reason isotretinoin, despite its significant side-effect profile, remains clinically effective after decades of use. ^[13]